Janssen Vaccines & Prevention B.v.

Isa Pharmaceuticals B.v.

Janssen Biotech, Inc.

Bavarian Nordic A/s

Selina Khan

Taco Gilles Uil

Evelien Margaretha Bunnik

Gerrit Christiaan Scheper

Koen Oosterhuis

Soumitra Roy

Jerôme H H V Custers

Jerôme Hubertina Henricus Victor Custers

Cornelis Johannes Maria Melief

Gijsbert Arie Van Der Marel

Ferdinand Antonius Ossendorp

Dmitri Viktorovitsj Filippov

Ricardo Attar

Jort Vellinga

Manuel Sepulveda

Markus Kalla

Jason DeHart

Vinod Krishna

Christian Maine

Jerome H Hv Custers

Katrin Weidner

Patrick Wilkinson

Jenifer Lum

Roland Zahn

Barbara Sanders

Evelien M Bunnik

Gerrit Ch Scheper

Provided are vaccines, polypeptides and polynucleotides based on mutant CALR and JAK2 sequences, vectors, host cells, viruses, and methods of making and using them. The disclosure also provides methods of inducing an immune response and methods of treating, preventing, reducing a risk of onset or delaying the onset of a clinical condition characterized by an expression of JAK2V617F or CALR exon 9 mutant, or both JAK2V617F and CALR exon 9 mutant, wherein the method comprises a plurality of administrations of any of the compositions comprising polynucleotides, polypeptides or vectors disclosed herein.

Vaccines based on mutant CALR and JAK2 and their uses

Provided herein are adenoviral nucleic acid sequences and adenoviral vectors comprising said nucleic acid sequences. The provided adenoviral vectors can be used to induce a protective immune response in a subject.

Adenovirus and uses thereof

Provided herein are chimeric adenoviral vectors. The provided chimeric adenoviral vectors can be used to induce a protective immune response in a subject.

Adenovirus vectors and uses thereof

Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV16.

Therapeutic HPV16 vaccines

Provided is designer nucleic acid constructs and polypeptides that can be used as therapeutic vaccines against HPV18 and/or HPV16.

Therapeutic HPV18 vaccines

Vectors, vaccines, vaccine compositions and vaccine combinations for use as therapeutics against HPV18 and/or HPV16 are described.

Therapeutic HPV vaccine combinations

The invention is directed to a compound according to the formula [1] wherein Rand Rare branched or straight groups having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, Y is sulphur or selene, X is S or O and R is &#x2014;OH or an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof. The invention is also directed to process for preparing said compound and the use of said compound as an adjuvant. The invention is also directed to a composition comprising said compound and the use of said composition, for example as a vaccine composition.

Adjuvant compound

The invention is directed to a compound according to the formula [1] wherein Rand Rare branched or straight groups having up to 17 atoms selected from carbon, nitrogen, oxygen and sulphur, n is 0 to and including 18, Y is sulphur or selene, X is S or 0 and R is &#x2014;OH or an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof. The invention is also directed to process for preparing said compound and the use of said compound as an adjuvant. The invention is also directed to a composition comprising said compound and the use of said composition, for example as a vaccine composition.

Growing community of inventors

Leiden, Netherlands

Selina Khan